52 results found.

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib; loperamide

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM).
afatinib; loperamide

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Dose escalation followed by treatment with MTD

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations.
Dose escalation followed by treatment with MTD

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Non-small Cell Lung Carcinoma Clinical Trial using chemotherapy

Yonsei University - Recruiting 18 years or older.
- .
chemotherapy

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Clinical Trial using bavituximab; Docetaxel; Placebo (for bavituximab)

Peregrine Pharmaceuticals - Recruiting 18 years or older.
- SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer.
bavituximab; Docetaxel; Placebo (for bavituximab)

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Small Cell Lung Carcinoma, or Malignant Epithelial Neoplasms Clinical Trial using (Belinostat) (PDX101); Cisplatin; Etoposide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin.
(Belinostat) (PDX101); Cisplatin; Etoposide

Small Cell Lung Carcinoma Clinical Trial using BAY1000394; Etoposide; Cisplatin; Carboplatin

Bayer - Recruiting 18 years or older.
- Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer.
BAY1000394; Etoposide; Cisplatin; Carboplatin

Solid Tumors, Lymphoma, or Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib; Gefitinib

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies.
LY2875358; Erlotinib; Gefitinib

Lung Cancer, Small Cell Clinical Trial using GSK2879552

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma.
GSK2879552

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line..

Carcinoma, Non-Small Cell Lung Clinical Trial using Radiation Therapy and EGFR-TKI target therapy

Tianjin Medical University Cancer Institute and Hospital - Recruiting 18 years to 70 years.
- A Phase II Study on the Safety and Efficacy of Radiation Therapy and Concurrent Erlotinib in Locally Advanced Non-small-cell Lung Cancer.
Radiation Therapy and EGFR-TKI target therapy

Carcinoma, Non-Small-Cell Lung Clinical Trial using PF-02341066

Pfizer - Recruiting 18 years or older.
- Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene.
PF-02341066

NSCLC (Non-small Cell Lung Cancer) Clinical Trial using Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Pfizer - Recruiting 18 years to 70 years.
- Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Non-Small Cell Lung Carcinoma Clinical Trial using CV9202

CureVac GmbH - Recruiting 18 years or older.
- An Exploratory, Open-label Phase Ib Study of RNActiver-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor.
CV9202

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer..

Small Cell Lung Carcinoma Clinical Trial using Ipilimumab; Placebo matching Ipilimumab; Etoposide; Cisplatin; Carboplatin

Bristol-Myers Squibb - Recruiting 18 years or older.
- Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC).
Ipilimumab; Placebo matching Ipilimumab; Etoposide; Cisplatin; Carboplatin

Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, or Irin Clinical Trial using Carfilzomib; Irinotecan

Cancer Research and Biostatistics Clinical Trials Consortium - Recruiting 18 years or older.
- Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy.
Carfilzomib; Irinotecan

Carcinoma, Non-small Cell Lung Clinical Trial using Dasatinib

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation.
Dasatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib; erlotinib

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy.
afatinib; erlotinib

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- THE SURVIVAL OF NON SMALL CELL LUNG CARCINOMA EGFR NON-MUTATED (WILD TYPE) PATIENTS TREATED WITH ERLOTINIB (TARCEVA) AFTER THE FAILURE OF AT LEAST ONE CHEMOTHERAPY REGIMEN..

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib.
LY2875358; Erlotinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib.
LY2875358; Erlotinib

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Carcinoma, Non-Small-Cell Lung, or Neoplasm Metastasis Clinical Trial using 34 Gy in a single fraction; 54Gy 18Gy/fr. x 3 fractions; 50Gy (12 x 5 fr.s); 60Gy (7.5Gy x 8fr.)

Institut Catal… d'Oncologia - Recruiting 18 years or older.
- Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases.
34 Gy in a single fraction; 54Gy 18Gy/fr. x 3 fractions; 50Gy (12 x 5 fr.s); 60Gy (7.5Gy x 8fr.)

Carcinoma, Non-Small-Cell Lung Clinical Trial using BIBW 2992; Sirolimus (rapamycin)

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib.
BIBW 2992; Sirolimus (rapamycin)

Solid Tumors, or Non-small Cell Lung Carcinoma Clinical Trial using DS-2248

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors.
DS-2248

Non-small Cell Lung Carcinoma Clinical Trial using None: Questionnaire Study

University Health Network, Toronto - Recruiting 18 years or older.
- Prospective Observational Study Of Patients With Asymptomatic Centrally Located Advanced NSCLC Who Are Not Suitable For Curative Treatment.
None: Questionnaire Study

NSCLC Clinical Trial using Icotinib of routine dose; Icotinib of high dose

Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years.
- An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease.
Icotinib of routine dose; Icotinib of high dose

Patients Must Have Histologically or Cytologically Confirmed Non- Clinical Trial using Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Paclictaxl, Carboplatin, and Bevcizumab.

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma.
Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Paclictaxl, Carboplatin, and Bevcizumab.

Carcinoma, Non-Small Cell Lung, or Carcinoma, Small Cell Lung Clinical Trial using 13-C-glucose

James Graham Brown Cancer Center - Recruiting 18 years to 75 years.
- Preoperative Metabolomic Analysis of Primary Lung Cancer: A Translational Clinical Trial of the Brown Cancer Center.
13-C-glucose

Non-small Cell Lung Cancer, Radiation Therapy, Locally Advanced D Clinical Trial using mid-position radiation strategy; ITV

Centre Leon Berard - Recruiting 18 years or older.
- Randomized Phase 2 Study Evaluating the Interest of Mid-position Strategy Versus ITV (Internal Target Volume) Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-resected Non-small Cell Lung Carcinoma (NSCLC)..
mid-position radiation strategy; ITV

Carcinoma, Small Cell Clinical Trial using Temozolomide

Chinese PLA General Hospital - Recruiting 18 years to 75 years.
- Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer.
Temozolomide

Advanced Malignancies, Carcinoma, Non-Small-Cell Lung, Anaplastic Clinical Trial using AP26113

Ariad Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113.
AP26113

NSCLC Clinical Trial using Olaparib; Cisplatin; Radiation

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma.
Olaparib; Cisplatin; Radiation

Carcinoma, Non-Small-Cell Lung Clinical Trial using BIBW 2992

University College, London - Recruiting 18 years or older.
- Phase II Trial of BIBW 2992 in Suspected Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy.
BIBW 2992

Carcinoma, Non-Small-Cell Lung Clinical Trial using Astagalus-based Formula: Qingshu-Yiqi-Tang

Chang Gung Memorial Hospital - Recruiting 18 years to 75 years.
- Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy.
Astagalus-based Formula: Qingshu-Yiqi-Tang

Carcinoma, Non Small Cell Lung Clinical Trial using Taxotere; Pemetrexed

Chonnam National University Hospital - Recruiting 18 years or older.
- A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer.
Taxotere; Pemetrexed

Carcinoma, Non Small Cell Lung Clinical Trial using CT Perfusion

University of Pittsburgh - Recruiting 18 years or older.
- CTP (Computed Tomography Perfusion) Imaging of Lung Cancer.
CT Perfusion

Non-small Cell Lung Cancer Metastatic, or Small Cell Lung Carcino Clinical Trial using therapeutic interventions

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network.
therapeutic interventions

Small Cell Carcinoma of Lung Clinical Trial using Irinotecan

Zhejiang Cancer Hospital - Recruiting 18 years to 75 years.
- Phase ? Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer.
Irinotecan

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous, or Carcinoma Clinical Trial using Docetaxel; Oxaliplatin

Korean South West Oncology Group - Recruiting 18 years or older.
- A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment.
Docetaxel; Oxaliplatin

Non-Small-Cell Lung Carcinoma Clinical Trial using cisplatin, vinorlebine, cetuximab; cisplatine, etoposide, cetuximab

Institut de Canc‚rologie de la Loire - Recruiting 18 years to 70 years.
- Feasibility of Cetuximab (ERBITUXr) Associated With Concomitant Radio-chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer: a Phase II, Randomised Study.
cisplatin, vinorlebine, cetuximab; cisplatine, etoposide, cetuximab

Carcinoma, Non-Small-Cell Lung, or Head and Neck Neoplasms Clinical Trial using [18F]-ML-10 in conjunction with PET imaging

Aposense Ltd. - Recruiting 18 years or older.
- A Prospective, Multicenter Study, to Evaluate the Efficacy and Safety of [18F]-ML-10, a Positron Emission Tomography (PET) Imaging Radiotracer, in Early Detection of Response of Non-Hematological Tumors to Concurrent Chemoradiotherapy.
[18F]-ML-10 in conjunction with PET imaging

Carcinoma, Non-Small-Cell Lung Clinical Trial using Endostatins; Docetaxel

Fudan University - Recruiting 18 years to 80 years.
- A Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients.
Endostatins; Docetaxel

Carcinoma, Non-Small-Cell Lung Clinical Trial using erlotinib plus docetaxel or pemetrexed; erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis - Recruiting 18 years or older.
- A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study).
erlotinib plus docetaxel or pemetrexed; erlotinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Gemcitabine and Docetaxel

Hospital Arnau de Vilanova - Recruiting 18 years or older.
- Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2.
Gemcitabine and Docetaxel

Carcinoma, Non-Small-Cell Lung Clinical Trial using Gefitinib; Radiation Therapy

Fudan University - Recruiting 18 years to 75 years.
- Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy.
Gefitinib; Radiation Therapy

Non Small Cell Lung Carcinoma Clinical Trial using Fractionated stereotactic body radiation therapy

AZ-VUB - Recruiting 18 years or older.
- Phase II Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma..
Fractionated stereotactic body radiation therapy

Carcinoma, Non-Small-Cell Lung Clinical Trial using Chemotherapy; Radiation Therapy

Clinical Oncology Research Associates - Recruiting N/A or older.
- Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study.
Chemotherapy; Radiation Therapy